



(51) International Patent Classification:

C07C 227/32 (2006.01) C07F 15/04 (2006.01)
C07C 229/36 (2006.01) C07D 317/54 (2006.01)
C07B 53/00 (2006.01) C07C 227/40 (2006.01)

(21) International Application Number:

PCT/IB2017/051757

(22) International Filing Date:

28 March 2017 (28.03.2017)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

201621010969 30 March 2016 (30.03.2016) IN

(71) Applicant: PIRAMAL ENTERPRISES LIMITED
[IN/IN]; Piramal Tower, Ganpatrao Kadam Marg, Lower
Parel, Mumbai 400013 (IN).(72) Inventors: GHARPURE, Milind; Light Hall A wing, Hir-
anandani Business Park, Saki Vihar Road, Chandivali,
Andheri(E), Mumbai 400072 (IN). JAGTAP, Ashutosh;
Light Hall A wing, Hiranandani Business Park, Saki Vihar
Road, Chandivali, Andheri(E), Mumbai 400072 (IN).
RAUT, Changdev; Light Hall A wing, Hiranandani Busi-
ness Park, Saki Vihar Road, Chandivali, Andheri(E),
Mumbai 400072 (IN). KANSAGARA, Nainesh; Light
Hall A wing, Hiranandani Business Park, Saki Vihar Road,
Chandivali, Andheri(E), Mumbai 400072 (IN). KRISH-
NAPILLAI, Jaisankar; Ennore Express Highway,
Ernavoor PO, Ennore, Chennai 600057 (IN). MANO-
HARAN, Nirmal Kumar; Ennore Express Highway,
Ernavoor PO, Ennore, Chennai 600057 (IN). PATIL,
Navnath; Light Hall A wing, Hiranandani Business Park,Saki Vihar Road, Chandivali, Andheri(E), Mumbai 400072
(IN).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,
BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN,
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA,
MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG,
NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS,
RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY,
TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ,
TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU,
TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE,
DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU,
LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK,
SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to the identity of the inventor (Rule 4.17(i))
- as to applicant's entitlement to apply for and be granted a
patent (Rule 4.17(ii))
- of inventorship (Rule 4.17(iv))

Published:

- with international search report (Art. 21(3))

(54) Title: AN IMPROVED PROCESS FOR THE PREPARATION OF DROXIDOPA AND ITS INTERMEDIATE

(57) Abstract: The present invention provides an improved process for preparation of L-threo-(2S,3R)-3-(3,4-dihydroxyphenyl)ser-
ine (I) (Droxidopa) and its salts; comprising (a) reaction of the aldehyde compound (III) (as described herein) with Metal complex
(II) (as described herein), and (b) hydrolysis of the compound (IV) obtained from step (a) in presence of acid. The present invention
also relates to a novel intermediates metal chiral complex (IV) for the preparation of Droxidopa.



AN IMPROVED PROCESS FOR THE PREPARATION OF DROXIDOPA AND ITS INTERMEDIATE


FIELD OF THE INVENTION

The present invention relates to an improved process for the preparation of *L-threo*-(2*S*,3*R*)-3-(3,4-dihydroxyphenyl)serine (I), which is known as Droxidopa and its pharmaceutically acceptable salts. The present invention also relates to a novel metal chiral complex (IV) as an intermediate used for the preparation of droxidopa.

BACKGROUND OF THE INVENTION

The following discussion of the prior art is intended to present the invention in an appropriate technical context, and allows its significance to be properly appreciated. Unless clearly indicated to the contrary, reference to any prior art in this specification should not be construed as an expressed or implied admission that such art is widely known or forms part of common general knowledge in the field.

Droxidopa is chemically known as (2*S*,3*R*)-2-amino-3-(3,4-dihydroxyphenyl)-3-hydroxypropanoic acid and it is structurally represented by the following formula (I). It is also known as *L-threo*-(2*S*,3*R*)-3-(3,4-dihydroxyphenyl)serine. Droxidopa is available in the market as Northera® capsules with dosages of 100 mg, 200 mg and 300 mg for oral administration.



Droxidopa (I)

NORTHERA® (droxidopa) capsules, for oral use is approved in the USA and is indicated for the treatment of orthostatic dizziness, light headedness, or the “feeling that you are about to black out”

in adult patients with symptomatic neurogenic orthostatic hypotension caused by primary autonomic failure, dopamine beta-hydroxylase deficiency, and non-diabetic autonomic neuropathy. Droxidopa is a synthetic amino acid analog that is directly metabolized to norepinephrine by dopadecarboxylase, which is extensively distributed throughout the body.

5 The drug was originally launched in 1989 in Japan by Sumitomo Dainippon Pharma for the oral treatment of frozen gait or dizziness associated with Parkinson's disease and for the treatment of orthostatic hypotension, syncope or dizziness associated with Shy-Drager syndrome and familial amyloidotic polyneuropathy.

10 Chirality has acquired increasing importance for the pharmaceutical industry, as evidenced by the fact that more than 80% of the drugs developed hitherto have chiral properties. The various enantiomers may develop completely different effects in the body, so that only one of two or more enantiomeric forms administered may be effective. In the case of Droxidopa (I), it has been observed that the *L-threo* enantiomer is the desired isomer having desired activity. Administration
15 of the active *L-threo* enantiomer of the compound (I), substantially free of its other isomers, would essentially enable a reduction in the dose of drug. Due to the importance of the *L-threo* enantiomer of the compound (I) as an oral, synthetic norepinephrine precursor, there exists a need to develop an economical and efficient synthetic process for its production.

20 US patent No. 3,920,728 (hereinafter US'728) provides a process for the preparation of droxidopa comprising reaction of 3,4-dibenzyloxybenzaldehyde with glycine, followed by treatment with sodium acetate trihydrate and diethylamine to obtain racemic-*threo/erythro*-3-(3,4-dibenzyloxyphenyl)-serine. Further, treatment of the compound with carbobenzoxy chloride to obtain racemic-*threo/erythro*-3-(3,4-dibenzyloxyphenyl)-N-carbobenzoxyserine and its treatment
25 with dicyclohexylamine to give racemic-*threo*-3-(3,4-dibenzyloxyphenyl)-N-carbobenzoxyserinedicyclohexylamine salt, which on treatment with HCl gas in the presence of ethyl acetate yields racemic-*threo*-3-(3,4-dibenzyloxyphenyl)-N-carbobenzoxyserine. Finally, treatment of the racemic serine compound with (+)-ephedrine to yield (+)-ephedrine salt of *L-threo*-3-(3,4-dibenzyloxyphenyl)-N-carbobenzoxyserine and hydrolysis of the compound to yield *L-threo*-
30 3-(3,4-dibenzyloxyphenyl)-N-carbobenzoxyserine; which on subsequent reduction over Pd/C provides *L-threo*-3-(3,4-dibenzyloxyphenyl)-serine.


The patent EP0024210B1 describes a process for preparation of optically active (D- or L-) threo-3-(3,4-dihydroxyphenyl)serine (Droxidopa) comprising reaction of racemic *threo*-3-(3,4-dibenzyloxyphenyl)-N-carbobenzoxys erine with a resolving agent, followed by decomposition using hydrochloric acid to yield (-)-3-(3,4-dibenzyloxyphenyl)-N-carbobenzoxys erine.

5


US Patent No. 4,562,263 (hereinafter US'263) discloses a process for preparation of droxidopa comprising optical resolution of N-phthaloyl-3-(3,4-methylenedioxyphenyl)serine using optically active amine selected from the group consisting of strychnine, cinchonidine, L-norephedrine, S-2-amino-1,1-diphenyl-1-propanol and L-3-hydroxy-3-(4-nitrophenyl)-2-amino-1-propanol to yield L-N-phthaloyl-3-(3,4-methylenedioxyphenyl)serine, reacting the resulting compound with a Lewis acid selected from the group consisting of aluminium trichloride, aluminium tribromide, boron trichloride and boron tribromide to form N-phthaloyl-3-(3,4-dihydroxyphenyl)-serine; which on further deprotection by removal of phthaloyl group with hydrazine to yield L-*threo*-3-(3,4-dihydroxyphenyl)-serine.

15



Research article *J. Am. Chem. Soc.* 107, 4252-59 (1985) disclosed a 'general method of Diastereo- and Enantioselective Synthesis of beta-Hydroxy-alpha-amino acids by condensation of aldehydes and ketones with Glycine' which involves formation of metal complex as:



The *J. Am. Chem. Soc.* 107, 4252-59 (1985) further disclosed hydrolysis of the metal complex to give desired compound.



Similarly, Journal of fluorine chemistry 75, 93-101, (1995) refers to the synthesis of 2- and 6-fluoro analogues of threo-3-(3,4-dihydroxyphenyl) serine (2- and 6-fluoro-threo-DOPS) comprises treatment of aldehyde compound with Ni^{++} followed by hydrolysis which is depicted below;



The published PCT application WO-A-2005/085178 disclosed the treatment of 1-hydroxy-1-(3, 4-dibenzoyloxyphenyl) glycine-Ni-D-2- [N- (N'- ben- zylpropyl) amino] benzophenone with

hydrochloric acid to obtain L-threo-(2S,3R)-3-(3,4-dibenzoyloxyphenyl) serine. As indicated, the said compound has both the hydroxyl group protected with benzyl group forms 3,4-dibenzoyloxyphenyl compound. The product on subsequent metal catalyzed hydrogenation, predominately using Pd/C under hydrogenation pressure provides Droxidopa.

A general method for the synthesis of enantiomerically pure beta-Hydroxy-alpha-amino acids and serine derivatives is also disclosed in the *J. Chem. Soc. Perkin Trans. 1*, 3143-54 (1993) and published patent application US 2015/0210667A1. US Patent No. 8,980,316 (hereinafter US'316) and published patent application US 2013/0253061A1 disclosed a composition of Droxidopa with

several particle size ranges in terms of 90% D (μm) values and average (μm) values.

It is evident from the above discussion that the prior art processes for the preparation of droxidopa involves multiple process steps such as resolution followed by separate deprotection method. The use of resolving agent renders the process costly. Partial recycling of the resolving agent is feasible but such recycling is costly as it requires additional processing and is also associated with waste generation. The undesired enantiomer cannot be recycled and is discarded.

The chiral resolution to obtain *threo/ erythro* isomer results into 50 % loss of the undesired isomer, which affects the overall yield of the process. Further, the process involves use of complex agents for isomer separation, which also results in < 50 % of desired isomer. Also, the hydrazine used for the deprotection of phthaloyl group is known to be genotoxic, and thus it is required to remove traces of hydrazine from the final product, droxidopa.

Thus, in view of these drawbacks there is a need to develop an alternative asymmetric synthesis which would provide the desired L-*threo* isomer in an efficient and more specific manner. The said prior art processes are therefore disadvantageous for commercial manufacturing due to non-feasibility of the reaction process owing to use of genotoxic reagents, and due to the elaborate and tedious nature of the process, providing low yield of the desired isomer.


Inventors of the present invention have developed an improved process which is a simple, efficient and cost-effective process and provides the desired compounds in improved yield and purity and that addresses the problems associated with the processes reported in the prior art. The process of the present invention does not involve use of any toxic and/or costly solvents, also does not involve use of costlier coupling agents and reagents. Moreover, the process does not require repetitive purification steps and column chromatography. Accordingly, the present invention provides a process for the preparation of droxidopa (I), which is simple, efficient, cost effective, environmentally friendly and commercially scalable for large scale operations.

SUMMARY OF THE INVENTION

In one aspect, the present invention relates to an improved process for the preparation of L-threo-(2S,3R)-3-(3,4-dihydroxyphenyl)serine (I) or a salt thereof; comprising (a) reaction of the aldehyde compound (III) (as described herein) with Metal complex (II) (as described herein), and (b) hydrolysis of the compound (IV) obtained from step (a) in presence of acid.


In one aspect, the present invention relates to an improved process for the preparation of L-threo-(2S,3R)-3-(3,4-dihydroxyphenyl)serine (I) or a salt thereof; comprising reaction of the aldehyde compound (III) (as described herein) with Metal complex (II) (as described herein) in the presence of a metal alkoxide to obtain compound (IV), followed by its hydrolysis in presence of acid.

In an embodiment, there is provided a novel intermediate metal complex (IV);



wherein M is a metal selected from Cu²⁺, Ni²⁺, or Zn²⁺ and R₁ is selected from a group consisting of hydrogen, unsubstituted or substituted alkyl, cycloalkyl, aryl, heterocyclic and protecting group;

In an embodiment, there is provided a novel intermediate Nickel complex (IVa);



In another aspect, the present invention relates to an improved process for the preparation of L-

threo-(2S,3R)-3-(3,4-dihydroxyphenyl)serine (I) or a salt thereof comprising (i) reaction of the aldehyde compound (IIIa) (as described herein) with Nickel complex (IIa) (as described herein), (ii) hydrolysis of the compound (IVa) obtained from step (i) in presence of acid, and (iii) treatment of the acid salt of compound (I) obtained from step (ii) with a base.

5

In one aspect, the present invention relates to an improved process for the preparation of *L-threo*-(2S,3R)-3-(3,4-dihydroxyphenyl)serine (I) or a salt thereof; comprising hydrolysis of the compound (IV) (as described herein) in presence of acid.

10 In an embodiment, there is provided *L-threo*-(2S,3R)-3-(3,4-dihydroxyphenyl)serine (I) with more than 99% ee.

In another aspect, the invention also provides a process for the purification of *L-threo*-(2S,3R)-3-(3,4-dihydroxyphenyl)serine (I) comprising treatment of compound (I) or its salt with a metal
15 hydride.

In another aspect, there is provided *L-threo*-(2S,3R)-3-(3,4-dihydroxyphenyl)serine (I) having particle size diameter range with a $d(0.1)$ of between about 1 to about 20 μm .

20 In another aspect, there is provided *L-threo*-(2S,3R)-3-(3,4-dihydroxyphenyl)serine (I) having particle size diameter range with a $d(0.5)$ of between about 5 to about 105 μm .

In another aspect, there is provided *L-threo*-(2S,3R)-3-(3,4-dihydroxyphenyl)serine (I) having particle size diameter range with a $d(0.9)$ of between about 10 to about 210 μm .

25


In another aspect, there is provided a pharmaceutical composition comprising a therapeutically effective amount of *L-threo*-(2S,3R)-3-(3,4-dihydroxyphenyl)serine (I) having particle size distribution range of $d(0.1)$ between about 1 to about 20 μm , $d(0.5)$ between about 5 to about 105 μm , $d(0.9)$ between about 10 to about 210 μm ; or any combination thereof.

30

In another aspect, there is provided *L-threo*-(2S,3R)-3-(3,4-dihydroxyphenyl)serine (I) having specific surface area value from 0.1 to 3 m^2/g .


DETAILED DESCRIPTION OF THE INVENTION

Accordingly, the present invention relates to an improved process for the preparation of *L-threo*-(2*S*,3*R*)-3-(3,4-dihydroxyphenyl)serine (I) or a salt thereof represented by the following formula,




5 comprising the steps of,

(a) preparation of metal complex (IV) represented by the following formula,



wherein M is a metal selected from Cu^{2+} , Ni^{2+} , or Zn^{2+}


by reacting the aldehyde (III) represented by the following formula,



10

wherein R_1 is selected from a group consisting of hydrogen, unsubstituted or substituted alkyl, cycloalkyl, aryl, heterocyclic and protecting group;

with Metal complex (II) represented by the following formula,



(II)

in the presence of a metal alkoxide; and

(b) hydrolyzing of the compound (IV) obtained from step (a) in presence of acid.

- 5 In the context of the present invention, the term 'hydrolysis' used in reference to any step of the reaction corresponds to the decomposition of metal complex (IV) and subsequent deprotection of the methylene dioxy group to yield dihydroxy compound of formula (I).

Accordingly, in the process of the present invention the intermediate metal complex compound (IV)
10 is optionally isolated during reaction, or in-situ converted to the compound (I) or its salt.

In an embodiment the 'metal alkoxide' is selected from the group consisting of sodium methoxide, sodium ethoxide, sodium isopropoxide, potassium methoxide, sodium tertiary butoxide, potassium tertiary butoxide, or mixtures thereof.

15 In an embodiment the 'acid' is selected from the group consisting of hydrochloric acid (HCl), hydrobromic acid, hydrofluoric acid, nitric acid, sulfuric acid and phosphoric acid or mixtures thereof.

20 In accordance with the embodiments of the present invention, the unsubstituted or substituted alkyl is (C₁-C₁₀)-alkyl, which may be a straight-chain or branched chain alkyl; for example, C₁-C₁₀ for straight chain and C₃-C₁₀ for branched chain. Suitable alkyl groups containing from one to ten carbon atoms, include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, t-butyl, iso-butyl, sec-butyl, n-pentyl, isopentyl, 2-pentyl, 3-pentyl, neo-pentyl, n-hexyl, isohexyl, 2-hexyl, 3-

hexyl, n-heptyl, isoheptyl, 2-heptyl, 3-heptyl, n-octyl, isooctyl, 2-octyl, 3-octyl, n-nonyl, isononyl, 2-nonyl, 3-nonyl, n-decyl, isodecyl, 2-decyl and 3-decyl.

Furthermore, the alkyl groups may be unsubstituted or substituted with one or more substituents. A substituted alkyl refers to a (C₁-C₁₀)-alkyl substituted with one or more groups, preferably 1-3 groups, independently selected from halogen, hydroxy, (C₁-C₆)-alkoxy, nitro, cyano, amino, substituted amines, C(O) and C(O)₂-alkyl.

In accordance with the embodiments of the present invention, the cycloalkyl is (C₁-C₁₂)-cycloalkyl, wherein a saturated or partially unsaturated cyclic hydrocarbon radical including 1, 2 or 3 rings and including a total of 3 to 12 carbon atoms forming the rings. The term cycloalkyl includes bridged, fused and spiro ring systems. Examples of cycloalkyl include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, adamantyl, norbornyl, bicyclo[2.1.0]pentane, bicyclo[2.2.1]heptyl, bicyclo[2.2.1]hept-2-ene, spiro[3.3]heptanes and 1,2,3,3a-tetrahydropentalene.

Furthermore, the cycloalkyl group may be unsubstituted or substituted with one or more groups, preferably 1-3 groups independently selected from halogen, hydroxy, (C₁-C₆)-alkoxy, nitro, cyano, amino, substituted amines, C(O) and C(O)₂-alkyl.

In accordance with the embodiments of the present invention, the aryl is (C₆-C₁₄)-aryl, which refers to monocyclic or bicyclic hydrocarbon groups having 6 to 14 ring carbon atoms, preferably 6 to 10 carbon atoms in which the carbocyclic ring(s) present have a conjugated pi electron system. Examples of (C₆-C₁₄)-aryl residues are phenyl, naphthyl, fluorenyl and anthracenyl. Aryl groups can be unsubstituted or substituted with one or more groups, for example 1, 2, 3, 4 or 5 groups independently selected from halogen, hydroxy, (C₁-C₆)-alkoxy, nitro, cyano, amino, substituted amines, C(O) and C(O)₂-alkyl.

In accordance with the embodiments of the present invention, the heterocyclic is a 3- to 9-membered saturated or partially unsaturated monocyclic or bicyclic ring system containing one to four identical or different hetero atoms selected from a nitrogen (N), a sulphur (S) or an oxygen (O) atom. Heterocyclyl includes saturated heterocyclic ring systems, which do not contain any double bond. Partially unsaturated heterocyclic ring systems containing at least one double bond, but do not form


an aromatic system containing hetero atom. Suitable saturated and partially unsaturated heterocyclic groups include, but are not limited to, aziridine, oxirane, oxiridine, thiirane, oxetane, azetidine, thietane, tetrahydrofuran, tetrahydrothiophene, pyrrolidine, dihydropyran, tetrahydropyran, thio-dihydropyran, thio-tetrahydropyran, piperidine, piperazine, morpholine, 1,3-oxazinane, 1,3-thiazinane, 4,5,6-tetra hydroypyrimidine, 2,3-dihydrofuran, dihydrothiene, dihydropyridine, tetrahydro pyridine, isoxazolidine, pyrazolidine, azepane, oxepane, thiepane and azocane.

Further, the heterocyclic having an aromatic ring containing heteroatom/s are herein referred to by the customary term "heteroaryl". Within the context of the present invention and as used herein, the term "heteroaryl" refers to a 5 to 10-membered aromatic monocyclic or bicyclic ring system containing one to four identical or different hetero atoms selected from N, S or an O atom. Examples of heteroaryl include, but are not limited to pyrrole, pyrazole, imidazole, triazole, pyrazine, furan, thiophene, oxazole, thiazole, benzimidazole, benzoxazole, benzothiazole, benzofuran, indole, indazole, isoindole, isoquinoline, isooxazole, triazine, purine, pyridine, quinoline, oxadiazole, thiene, pyridazine, pyrimidine, isothiazole, quinoxaline (benzopyrazine), tetrazole, azepine, oxepine, thiepine and azocine. The oxidized form of the ring nitrogen atom of the heteroaryl to provide N-oxide is also encompassed.

Furthermore, the heterocyclic group may be unsubstituted or substituted with one or more groups, preferably 1-3 groups independently selected from halogen, hydroxy, (C₁-C₆)-alkoxy, nitro, cyano, amino, substituted amines, C(O) and C(O)₂-alkyl.

In accordance with the embodiments of the present invention, the 'protecting group' is an hydroxyl protecting group which refers to the group tosyl, mesyl, nosyl, acetyl, benzoyl, substituted benzoyl, benzyl, substituted benzyl, dimethoxy trityl, methoxy trityl, and the like.


Accordingly, in an embodiment the present invention relates to an improved process for the preparation of *L-threo*-(2S,3R)-3-(3,4-dihydroxyphenyl)serine (I) represented by the following formula,



(I)


comprising the steps of,

(i) preparation of metal complex (IVa) represented by the following formula,




(IVa)

5 by reacting the 2-ethoxybenzo[d][1,3]dioxole-5-carbaldehyde (IIIa) represented by the following formula,



(IIIa)

with Metal complex (IIa) represented by the following formula,




(IIa)

10 in the presence of sodium methoxide;

(ii) hydrolysis of the compound (IVa) obtained from step (i) in presence of acid to obtain salt of

compound (I) represented by the following formula,



(iii) treatment of the acid salt of compound (I) obtained from step (ii) with a base.

5 In an embodiment, the acid is hydrochloric acid.


In an embodiment, the base is triethylamine.

In a specific embodiment, the process for the preparation of *L-threo*-(2*S*,3*R*)-3-(3,4-dihydroxyphenyl)serine (I) comprises the steps of;

- 10 (1) adding the compound (III) in a solvent,
- (2) adding metal alkoxide and the compound (II) to the reaction mixture of step (1),
- (3) optionally isolating the compound (IV),
- (4) adding an acid to the stirring solution containing compound (IV),
- (5) optionally isolating salt of compound (I) of step (4),
- 15 (6) adding a base to the stirring solution containing salt of compound (I),
- (7) isolating the desired product.

The process of the present invention as per the specific embodiment described above is illustrated in the following Scheme (I),

20



Scheme (I)

The solvent used in the step (1) to step (7) of the above process (as depicted in the Scheme-I) is selected from a halogenated solvent such as dichloromethane, 4-bromotoluene, diiodomethane, carbon tetrachloride, chlorobenzene and chloroform; alcoholic solvent such as methanol, ethanol, isopropanol, t-amyl alcohol, t-butyl alcohol and hexanol; an ether solvent such as tetrahydrofuran, cyclopentyl methyl ether, 2-methyltetrahydrofuran, diethyl ether and 1,4-dioxane; a ketone selected from methyl ethyl ketone, acetone; an aprotic solvent such as acetonitrile, N,N-dimethyl formamide (DMF), N,N-dimethyl acetamide, dimethyl sulfoxide (DMSO) and N-methylpyrrolidone (NMP); an aromatic solvent such as toluene, xylene and benzene; acetone; water or a mixture thereof

The metal alkoxide used in the step (2) of the above process (as depicted in the Scheme (I)) is selected from the sodium methoxide, sodium ethoxide, sodium isopropoxide, potassium methoxide, sodium tertiary butoxide, potassium tertiary butoxide, or mixtures thereof.


The term 'isolating' referred to in the step (3), step (5) and step (7) of the above process (as depicted in the Scheme (I)) corresponds to the steps involving biphasic separation, separation of organic phase, filtration, evaporation of solvent, cooling, precipitation, washing and/or drying.

The acid used in the step (4) of the above process (as depicted in the Scheme (I)) is selected from hydrochloric acid, hydrobromic acid, hydrofluoric acid, nitric acid, sulfuric acid and phosphoric acid or mixtures thereof.

- 5 The base used in the step (6) of the above process (as depicted in the Scheme (I)) is selected from an organic base or an inorganic base such as triethylamine (TEA), N,N-diisopropylethylamine, tripropylamine, pyridine, sodium carbonate, sodium bicarbonate, potassium carbonate, sodium hydroxide, potassium hydroxide, lithium hydroxide, lithium carbonate, sodium bicarbonate, potassium bicarbonate, sodium hydride, or a mixture thereof.

10

The overall process of the present invention involving preparation of droxidopa (I) via formation of intermediate compound (IVa) is illustrated in the following Scheme (II):



Scheme (II)

- 15 The process illustrated in the above scheme (II) comprises reaction of the compound (IIa) with 2-ethoxybenzo[d][1,3]dioxole-5-carbaldehyde (IIIa) in the presence of a metal alkoxide selected from sodium methoxide to obtain compound (IVa) which is optionally isolated or in-situ hydrolysed by the treatment with an acid selected from hydrochloric acid to obtain salt of droxidopa (I). The salt was treated with a base selected from triethylamine in aqueous medium and the desired product was

obtained with more than 99% ee.

In an embodiment, there is provided *L-threo*-(2S,3R)-3-(3,4-dihydroxyphenyl)serine (I) with Nickel (Ni) content less than 30 ppm.

5

In an embodiment, there is provided *L-threo*-(2S,3R)-3-(3,4-dihydroxyphenyl)serine (I) with Nickel (Ni) content less than 20 ppm.

10 In an embodiment, there is provided *L-threo*-(2S,3R)-3-(3,4-dihydroxyphenyl)serine (I) with Nickel (Ni) content less than 10 ppm.

The inventors of the process of the instant invention observed that the elemental impurity content of the final product (Droxidopa) obtained by this process is very low and does not require any specific purification technology to remove elemental impurities such Nickel (Ni).

15

The following Table-1 indicated Nickel content in the final product (Droxidopa) obtained by the process of the instant invention:

Sample	Parameter	Result (Ni content)
Sample 1	Nickel by ICP	7.521 ppm
Sample 2	Nickel by ICP	3.711 ppm
Sample 3	Nickel by ICP	12.11 ppm
Sample 4	Nickel by ICP	19.75 ppm

20

Table-1


Accordingly, it is also evident that the product Droxidopa (I) obtained by the process of the instant invention has a high enantiomeric excess (ee).

25 In an another embodiment, there is provided *L-threo*-(2S,3R)-3-(3,4-dihydroxyphenyl)serine (I) with more than 99% ee.

In an another embodiment, there is provided *L-threo*-(2S,3R)-3-(3,4-dihydroxyphenyl)serine (I) with more than 99.5% ee.


In an another embodiment, there is provided *L-threo*-(2S,3R)-3-(3,4-dihydroxyphenyl)serine (I) with more than 99.99% ee.

In an embodiment, there is provided a novel intermediate metal complex (IV);




wherein; M is a metal selected from Cu^{2+} , Ni^{2+} , or Zn^{2+} ; and R_1 is selected from a group consisting of hydrogen, unsubstituted or substituted alkyl, cycloalkyl, aryl, heterocyclic and protecting group.


In an embodiment, there is provided a novel intermediate Nickel complex (IVa);



Accordingly in yet another aspect, the present invention relates to an improved process for the preparation of *L-threo*-(2S,3R)-3-(3,4-dihydroxyphenyl)serine (I) or a salt thereof represented by the following formula,



comprising hydrolysis of the compound (IV) represented by the following formula,



wherein M and R₁ are as defined above; in the presence of an acid.

- 5 In another aspect, the invention also provides a process for the purification of *L-threo*-(2*S*,3*R*)-3-(3,4-dihydroxyphenyl)serine (I) comprising treatment of compound (I) or its salt with a metal hydride.

10 In an embodiment, there is provided a method for the purification of Droxidopa (I) or its salts using a metal hydride.

In an another specific embodiment, the process for the preparation of pure *L-threo*-(2*S*,3*R*)-3-(3,4-dihydroxyphenyl)serine (I) having total impurity less than 0.06% comprises the steps of;

- (p) adding Droxidopa (I) salt to a solvent,
 15 (q) adding a metal hydride to the stirring solution of step (p),
 (r) isolating pure Droxidopa (I) salt or its free base.

In an embodiment, the solvent used in the step (p) of the above process is selected from water; a halogenated solvent such as dichloromethane, 4-bromotoluene, diiodomethane, carbon tetrachloride, chlorobenzene and chloroform; alcoholic solvent such as methanol, ethanol, isopropanol, t-amyl alcohol, t-butyl alcohol and hexanol; an ether solvent such as tetrahydrofuran, cyclopentyl methyl ether, 2-methyltetrahydrofuran, diethyl ether and 1,4-dioxane; a ketone selected from methyl ethyl ketone, acetone; an aprotic solvent such as acetonitrile, N,N-dimethyl formamide (DMF), N,N-dimethyl acetamide, dimethyl sulfoxide (DMSO) and N-methylpyrrolidone (NMP); an aromatic solvent such as toluene, xylene and benzene; acetone; or a mixture thereof.

20
25

In an embodiment, the metal hydride used in the step (q) of the above process is selected from boron hydride, lithium borohydride, sodium borohydride, potassium borohydride, sodium cyanoborohydride, sodium dialkylamine borohydride, dialkyl aluminum hydride, aluminum hydride, sodium aluminum hydride, lithium aluminum hydride, sodium hydride, potassium hydride, rubidium hydride and cesium hydride or mixture thereof.

As illustration, the purification process comprises, dissolving the Droxidopa (I) hydrochloride salt (35 g) in the demineralized water followed by the addition of concentrated HCl and further dropwise addition of 0.1% w/w sodium borohydride solution in 4 volumes (V) of demineralized (DM) water (with respect to weight of HCl salt). The reaction mixture was filtered, treated with activated carbon and passed through hyflo[®] bed to provide the pure aqueous solution of *L-threo*-(2S,3R)-3-(3,4-dihydroxyphenyl)serine (I) hydrochloride with impurity less than 0.06%; which is further treated with a base to obtain its free base that is pure *L-threo*-(2S,3R)-3-(3,4-dihydroxyphenyl)serine (I) (Droxidopa).

The inventors of the process of the instant invention observed that the total impurity content of the Droxidopa obtained by this process is very low as less than 0.06%.

The following Table-2 indicated impurity content in the final product (Droxidopa) obtained by the process of the instant invention:

Sample	HPLC purity
Sample 1	99.9%, any individual known impurity 0.04%
Sample 2	99.8%, any individual known impurity 0.04%
Sample 3	99.9%, any individual known impurity 0.05%
Sample 4	99.9%, any individual known impurity 0.05%

Table-2

In another aspect, there is provided *L-threo*-(2S,3R)-3-(3,4-dihydroxyphenyl)serine (I) having

particle size diameter range with a d(0.1) of between about 1 to about 20 μm .

In another aspect, there is provided *L-threo*-(2S,3R)-3-(3,4-dihydroxyphenyl)serine (I) having particle size diameter range with a d(0.5) of between about 5 to about 105 μm .

5

In another aspect, there is provided *L-threo*-(2S,3R)-3-(3,4-dihydroxyphenyl)serine (I) having particle size diameter range with a d(0.9) of between about 10 to about 210 μm .

The following Table-3 indicates the particle size range of Droxidopa (I) as observed by the inventors:

10

Droxidopa particle size d(0.1) μm	Before milling	After milling
	9.49	3.02
	18.33	2.37
	5.4	2.08

Droxidopa particle size d(0.5) μm	Before milling	After milling
	54.77	14.25
	103.87	5.93
	38.3	9.52

Droxidopa particle size d(0.9) μm	Before milling	After milling
	190.7	57.78
	207.5	12.55
	97.3	29.15

15

Table-3

The above particle size ranges were observed when measured by Malvern Mastersizer particle size analyzer equipped with a 30 mm lens Mastersizer 2000, SCIROCCO 2000, air compressor and

20

vacuum pump. In general, the particle size distribution may be achieved by the process of the present invention or alternatively by any one of the known methods reported in the art like milling, micronization, grinding or sieving, which may reduce the particle.

5 Accordingly, there is provided L-*threo*-(2S,3R)-3-(3,4-dihydroxyphenyl)serine (I) having a particle size diameter range with a d(0.1) of between about 5 to about 20 μm , before milling.

Accordingly, there is provided L-*threo*-(2S,3R)-3-(3,4-dihydroxyphenyl)serine (I) having a particle size diameter range with a d(0.1) of between about 1 to about 5 μm , after milling.

10

Accordingly, there is provided L-*threo*-(2S,3R)-3-(3,4-dihydroxyphenyl)serine (I) having a particle size diameter range with a d(0.5) of between about 35 to about 105 μm , before milling.

15 Accordingly, there is provided L-*threo*-(2S,3R)-3-(3,4-dihydroxyphenyl)serine (I) having a particle size diameter range with a d(0.5) of between about 5 to about 15 μm , after milling.

Accordingly, there is provided L-*threo*-(2S,3R)-3-(3,4-dihydroxyphenyl)serine (I) having a particle size diameter range with a d(0.9) of between about 95 to about 210 μm , before milling.

20 Accordingly, there is provided L-*threo*-(2S,3R)-3-(3,4-dihydroxyphenyl)serine (I) having a particle size diameter range with a d(0.9) of between about 10 to about 60 μm , after milling.

25 In another aspect, there is provided a pharmaceutical composition comprising a therapeutically effective amount of L-*threo*-(2S,3R)-3-(3,4-dihydroxyphenyl)serine (I) having particle size distribution range of d(0.1) between about 1 to about 20 μm , d(0.5) between about 5 to about 105 μm , d(0.9) between about 10 to about 210 μm ; or any combination thereof.

In another aspect, there is provided L-*threo*-(2S,3R)-3-(3,4-dihydroxyphenyl)serine (I) having specific surface area value from 0.1 to 3 m^2/g .

30

In an embodiment, there is provided L-*threo*-(2S,3R)-3-(3,4-dihydroxyphenyl)serine (I) having surface area BET gas absorption value of from 0.1 to 3 m^2/g ; preferably from 0.12 to 2 m^2/g ; more

preferably from 0.14 to 1.5 m²/g.

The invention is further illustrated by the following examples which are provided to be exemplary of the invention, and do not limit the scope of the invention. While the present invention has been described in terms of its specific embodiments, certain modifications and equivalents will be apparent to those skilled in the art and are intended to be included within the scope of the present invention.

EXAMPLES

Example-1: Preparation of Nickel complex (IVa)

Charged 300 mL of methanol in a flask followed by the addition of Nickel complex (IIa) (100 g) at temperature of about 25-30°C. To the stirring solution was added 120 mL of 25% Sodium methoxide solution and (40.9 g) aldehyde compound (IIIa). The reaction mixture was stirred for about 1 hour and quenched in acetic acid: water mixture (200 mL of 20 % acetic acid & 1000 mL of demineralized (DM) water). The reaction mixture was filtered and solid washed with 300 mL of DM water. The residue was treated with (600 mL) to obtain desired product (HPLC purity: 83.4%)

Example-2: Preparation of L-threo-(2S,3R)-3-(3,4-dihydroxyphenyl)serine (I)

Charged 300 mL of methanol in a flask followed by the addition of Nickel complex (IVa) (30 g) at temperature of about 25-30°C. To the stirring solution was added (75 mL) of 5N HCl and the reaction mixture was heated to 40°C. After 2 hours, the reaction was cooled to 25-30°C and concentrated under vacuum. The residue of crude Droxidopa hydrochloride salt was converted to its free base by adjusting the pH to 7.5-8.5 with 25% triethylamine in methanol solution in 5 volumes (V) (w.r.t weight. of HCl salt) DM water medium for about 1 hour. The solid was filtered and washed with (2 X 4V) of DM water and (2 X 7V) of methanol to obtain desired product. (Yield 76%, chiral purity 99.65% (ee)).

Example-3: Preparation of L-threo-(2S,3R)-3-(3,4-dihydroxyphenyl)serine (I) hydrochloride.

Charged 420 mL of methanol in a flask followed by the addition of sodium methoxide solution (55 mL), Nickel complex (IIa) (100 g) and aldehyde compound (IIIa). The reaction mixture was stirred at temperature of about 15-20°C for about 1 hour. The reaction mixture was further cooled to about 10 °C temperature; to the reaction mixture was added concentrated hydrochloric acid (100 mL) and

stirred for 3 hours at elevated temperature of about 40°C. The reaction mixture was filtered and washed with aqueous HCl. The aqueous filtrate was separately treated with methylene dichloride (350 mL) and ethyl acetate (350 mL) respectively. The separated aqueous layer was cooled to -5 - 5 °C of temperature and stirred for about 3 hour to obtain solid precipitate of *L-threo*-(2S,3R)-3-(3,4-dihydroxyphenyl)serine (I) HCl salt. The obtained (I) HCl salt was recrystallized from isopropyl alcohol (Yield: 85%, chiral purity 99.99% ee).

Example-4: Preparation of *L-threo*-(2S,3R)-3-(3,4-dihydroxyphenyl)serine (I)

The Droxidopa hydrochloride salt (100 g) was converted to free base by adjusting the pH to 7.5 - 8.5 of its aqueous solution using triethylamine (150 mL) in methanol (150 mL) as solution. The solid was filtered and washed with water (100 mL) followed by washing with methanol (100 mL) to obtain desired product. (Yield: 65g (76.5 %), chiral purity 99.99 % ee).


Example-5: Purification of Preparation of *L-threo*-(2S,3R)-3-(3,4-dihydroxyphenyl)serine (I) hydrochloride.

Charged droxidopa hydrochloride (35 g) in a flask followed by the addition of demineralized water (10 V) and concentrated HCl (0.5 V) (volumes with respect to weight of HCl salt); the reaction mixture was stirred at temperature of about 25-30°C. To the reaction mass was added 0.1% w/w sodium borohydride in 4 V of DM water (with respect to weight of HCl salt) and further continued stirring at temperature of about 25-30°C for about 30 minutes. The reaction mixture was filtered, treated with activated carbon and passed through hyflo bed. Obtained the pure aqueous solution of *L-threo*-(2S,3R)-3-(3,4-dihydroxyphenyl)serine (I) hydrochloride with impurity less than 0.06%.

The pure (I) HCl salt was further converted to its free base that is *L-threo*-(2S,3R)-3-(3,4-dihydroxyphenyl)serine (I) (Droxidopa) using the method disclosed under Example-4.

We claim


1. A process for the preparation of *L-threo*-(2*S*,3*R*)-3-(3,4-dihydroxyphenyl)serine (I) or its salt; of the following formula,



5

comprising the steps of,


- (a) reacting the compound (III) of the following formula,



wherein R₁ is selected from a group consisting of hydrogen, unsubstituted or substituted alkyl, cycloalkyl, aryl, heterocyclic and protecting group;

10


with a metal complex (II) of the following formula,




wherein 'M' is a metal selected from Cu²⁺, Ni²⁺, or Zn²⁺

- (b) hydrolyzing of the compound (IV) of the following formula obtained from step (a) in

presence of an acid,




2. A process for the preparation of *L-threo*-(2*S*,3*R*)-3-(3,4-dihydroxyphenyl)serine (I) of the following formula,




comprising the steps of,

- (i) reacting the compound (III) of the following formula,




wherein R₁ is selected from a group consisting of hydrogen, unsubstituted or substituted alkyl, cycloalkyl, aryl, heterocyclic and protecting group;

with a metal complex (II) of the following formula,




(II)

(ii) hydrolyzing the compound (IV) of the following formula obtained from step (i) in presence of an acid,



(IV)

5 (iii) treating the acid salt of compound (I) of the following formula obtained from step (ii) with a base,




(I). salt

3. The process according to the claim 1 or claim 2, wherein the step (a) or step (i) is performed in the presence of a metal alkoxide which is selected from the group consisting of sodium methoxide, sodium ethoxide, sodium isopropoxide, potassium methoxide, sodium tertiary butoxide, potassium tertiary butoxide and/or mixtures thereof.
4. The process according to the claim 1 or claim 2, wherein the acid at step (b) or step (ii) is selected from the group consisting of hydrochloric acid, hydrobromic acid, hydrofluoric


acid, nitric acid, sulfuric acid and phosphoric acid or mixtures thereof.

5. The process according to the claim 2, wherein the base at step (iii) is an organic base or an inorganic base selected from the group consisting of triethylamine (TEA), N,N-diisopropylethylamine, tripropylamine, pyridine, sodium carbonate, sodium bicarbonate, potassium carbonate, sodium hydroxide, potassium hydroxide, lithium hydroxide, lithium carbonate, sodium bicarbonate, potassium bicarbonate, sodium hydride, or a mixture thereof.
6. The process according to the claim 1 or claim 2, wherein the product Droxidopa (I) is obtained having >99% enantiomeric excess (ee).
7. A compound L-*threo*-(2S,3R)-3-(3,4-dihydroxyphenyl)serine (I) (Droxidopa) with >99% ee.
8. A compound L-*threo*-(2S,3R)-3-(3,4-dihydroxyphenyl)serine (I) (Droxidopa) with ee >99.5%.
9. A compound: metal complex (IV) of following formula;




wherein 'M' is a metal selected from Cu^{2+} , Ni^{2+} , or Zn^{2+} ; and R_1 is selected from a group consisting of hydrogen, unsubstituted or substituted alkyl, cycloalkyl, aryl, heterocyclic and protecting group.


10. A compound: Nickel complex (IVa) of following formula;



11. A process for the preparation of *L-threo*-(2*S*,3*R*)-3-(3,4-dihydroxyphenyl)serine (I) or its salt; of the following formula,




comprising hydrolysis of the compound (IV) of the following formula, in the presence of an acid




wherein 'M', 'R₁' and 'acid' are as defined in any of the claims 1, 2, 4 or 9.

12. A process for the preparation of *L-threo*-(2*S*,3*R*)-3-(3,4-dihydroxyphenyl)serine (I) of the following formula,




comprising the steps of,

- (i) reacting the compound (IIIa) of the following formula,




(IIIa)

with a metal complex (IIa) of the following formula,




(IIa)

(ii) hydrolyzing the compound (IVa) of the following formula obtained from step (i) in presence of hydrochloric acid,



(IVa)

(iii) treating the HCl salt of compound (I) of the following formula obtained from step (ii) with a triethylamine,



(I). HCl

13. A compound *L-threo*-(2S,3R)-3-(3,4-dihydroxyphenyl)serine (I) (Droxidopa) with Nickel (Ni) content less than 30 ppm.

14. A compound *L-threo*-(2S,3R)-3-(3,4-dihydroxyphenyl)serine (I) (Droxidopa) with Nickel

(Ni) content less than 20 ppm.

15. A process for the purification of L-*threo*-(2S,3R)-3-(3,4-dihydroxyphenyl)serine (I) comprising treatment of compound (I) or its salt with a metal hydride.

5

16. A process for the purification of L-*threo*-(2S,3R)-3-(3,4-dihydroxyphenyl)serine (I) comprising the steps of;

(p) adding Droxidopa (I) salt to a solvent,

(q) adding a metal hydride to the stirring solution of step (p),

10

(r) isolating pure Droxidopa (I) salt or its free base.

17. The process according to the claim 15 or claim 16, wherein the product Droxidopa (I) is obtained having the total impurity content less than 0.06%.

15

18. The process according to the claim 15 or claim 16, wherein the metal hydride is selected from the group consisting of boron hydride, lithium borohydride, sodium borohydride, potassium borohydride, sodium cyanoborohydride, sodium dialkylamine borohydride, dialkyl aluminum hydride, aluminum hydride, sodium aluminum hydride, lithium aluminum hydride, sodium hydride, potassium hydride, rubidium hydride, cesium hydride or mixture thereof.

20

19. The process according to the claim 16, wherein the solvent is selected from the group consisting of water, halogenated solvent, alcoholic solvent, ether solvent, ketone solvent, aromatic solvent, an aprotic solvent such as acetonitrile, N,N-dimethyl formamide (DMF), N,N-dimethyl acetamide, dimethyl sulfoxide (DMSO) and N-methylpyrrolidone (NMP) or mixture thereof.

25

20. A compound L-*threo*-(2S,3R)-3-(3,4-dihydroxyphenyl)serine (I) (Droxidopa) having particle size diameter range with a d(0.1) of between about 1 to about 20 μm .

30

21. A compound L-*threo*-(2S,3R)-3-(3,4-dihydroxyphenyl)serine (I) (Droxidopa) having particle size diameter range with a d(0.5) of between about 5 to about 105 μm .

22. A compound *L-threo*-(2S,3R)-3-(3,4-dihydroxyphenyl)serine (I) (Droxidopa) having particle size diameter range with a d(0.9) of between about 10 to about 210 μm .

23. A pharmaceutical composition comprising a therapeutically effective amount of *L-threo*-(2S,3R)-3-(3,4-dihydroxyphenyl)serine (I) having particle size distribution range of d(0.1) between about 1 to about 20 μm , d(0.5) between about 5 to about 105 μm , d(0.9) between about 10 to about 210 μm ; or any combination thereof.

24. A compound *L-threo*-(2S,3R)-3-(3,4-dihydroxyphenyl)serine (I) (Droxidopa) having specific surface area value from 0.1 to 3 m^2/g .

INTERNATIONAL SEARCH REPORT

 International application No.
PCT/IB2017/051757

A. CLASSIFICATION OF SUBJECT MATTER

C07C 227/32 (2006.01) C07C 229/36 (2006.01) C07B 53/00 (2006.01) C07F 15/04 (2006.01) C07D 317/54 (2006.01)
C07C 227/40 (2006.01)

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

STN: Chemical Abstract Registry, CAlus and CASreact. Substructure search based on compounds of formula (I), (III) and (IV).

Patentscope and Espacenet: Applicant(s)/Inventor(s) name search

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
	Documents are listed in the continuation of Box C	



Further documents are listed in the continuation of Box C



See patent family annex

* "A"	Special categories of cited documents: document defining the general state of the art which is not considered to be of particular relevance	"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"E"	earlier application or patent but published on or after the international filing date	"X"	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"L"	document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y"	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"O"	document referring to an oral disclosure, use, exhibition or other means	"&"	document member of the same patent family
"P"	document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search 8 June 2017	Date of mailing of the international search report 08 June 2017
Name and mailing address of the ISA/AU AUSTRALIAN PATENT OFFICE PO BOX 200, WODEN ACT 2606, AUSTRALIA Email address: pct@ipaustalia.gov.au	Authorised officer Ben Harris AUSTRALIAN PATENT OFFICE (ISO 9001 Quality Certified Service) Telephone No. 0262832272

Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
the subject matter listed in Rule 39 on which, under Article 17(2)(a)(i), an international search is not required to be carried out, including
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a)

Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

See Supplemental Box for Details

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☒ As all searchable claims could be searched without effort justifying additional fees, this Authority did not invite payment of additional fees.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee.
- ☐ The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT		International application No.
C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		PCT/IB2017/051757
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 2005/085178 A1 (ESTECHPHARMA CO., LTD.) 15 September 2005 examples 1-6 pages 10-13	1-6 and 9-12
X	WO 2013/142093 A1 (CHELSEA THERAPEUTICS, INC.) 26 September 2013 pages 20-23	7-8 and 13-14
X	US 2009/0074861 A1 (OCHIAI et al.) 19 March 2009 Table 11 pages 7-8, and para [0082]	20-24
A	McOmie, J. F. W., "Protective Groups in Organic Chemistry", Springer, 1976, ISBN 978-1-4684-72220-2, pages 130-131 section 3.2.1.7 'Cyclic Orthoesters' pages 130-131	1-24

Supplemental Box**Continuation of: Box III**

This Authority has found that there are different inventions based on the following features that separate the claims into distinct groups:

Invention 1 - Claims 1-6 and 9-12 (in full): Synthesis of Droxidopa (I) using metal complex (II), and metal complex intermediates thereof (IV).

Invention 2 - Claims 7-8 (in full): Droxidopa with high enantiomeric excess.

Invention 3 - Claims 13-14 (in full): Droxidopa with low nickel impurities present.

Invention 4 - Claims 15-19 (in full): Processes for purifying Droxidopa by treatment with a metal hydride.

Invention 5 - Claims 20-24 (in full): Droxidopa having particle size diameter in specified ranges.

PCT Rule 13.2, first sentence, states that unity of invention is only fulfilled when there is a technical relationship among the claimed inventions involving one or more of the same or corresponding special technical features. PCT Rule 13.2, second sentence, defines a special technical feature as a feature which makes a contribution over the prior art.

When there is no special technical feature common to all the claimed inventions there is no unity of invention.

In the above groups of claims, the identified features may have the potential to make a contribution over the prior art but are not common to all the claimed inventions and therefore cannot provide the required technical relationship. The only feature common to all of the claimed inventions and which provides a technical relationship among them is Droxidopa. However this feature does not make a contribution over the prior art because it is disclosed in:

D1: WO 2005/085178 A1 (ESTECHPHARMA CO., LTD.) 15 September 2005

D2: WO 2013/142093 A1 (CHELSEA THERAPEUTICS, INC.) 26 September 2013

D3: US 2009/0074861 A1 (OCHIAI et al.) 19 March 2009

Therefore in the light of this document this common feature cannot be a special technical feature. Therefore there is no special technical feature common to all the claimed inventions and the requirements for unity of invention are consequently not satisfied *a posteriori*.

INTERNATIONAL SEARCH REPORT		International application No.	
Information on patent family members		PCT/IB2017/051757	
This Annex lists known patent family members relating to the patent documents cited in the above-mentioned international search report. The Australian Patent Office is in no way liable for these particulars which are merely given for the purpose of information.			
Patent Document/s Cited in Search Report		Patent Family Member/s	
Publication Number	Publication Date	Publication Number	Publication Date
WO 2005/085178 A1	15 September 2005	WO 2005085178 A1	15 Sep 2005
		JP 2005247828 A	15 Sep 2005
		JP 4170990 B2	22 Oct 2008
		KR 100458983 B1	19 Nov 2004
WO 2013/142093 A1	26 September 2013	WO 2013142093 A1	26 Sep 2013
		US 2013253061 A1	26 Sep 2013
US 2009/0074861 A1	19 March 2009	US 2009074861 A1	19 Mar 2009
		US 8980316 B2	17 Mar 2015
		CA 2608690 A1	23 Nov 2006
		CN 101180046 A	14 May 2008
		CN 101180046 B	28 Dec 2011
		EP 1886678 A1	13 Feb 2008
		EP 1886678 B1	19 Apr 2017
		HK 1120726 A1	12 Oct 2012
		JP 5219508 B2	26 Jun 2013
		JP 2009185083 A	20 Aug 2009
		JP 5219924 B2	26 Jun 2013
		KR 20080013907 A	13 Feb 2008
		KR 101435199 B1	28 Aug 2014
		WO 2006123678 A1	23 Nov 2006
End of Annex			
Due to data integration issues this family listing may not include 10 digit Australian applications filed since May 2001.			
Form PCT/ISA/210 (Family Annex)(July 2009)			